| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/29/2009 | CN100519553C Inhiitors of cyclin dependent kinases as anti-cancer agent |
| 07/29/2009 | CN100519539C N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 07/29/2009 | CN100519527C Inhibitors of histone deacetylase |
| 07/29/2009 | CN100518817C Therapeutic agent to recover hematopoiesis function and its compositions and usage |
| 07/29/2009 | CN100518748C Emulsion containing plant extract, method for producing said emulsion and for obtaining plant extract |
| 07/29/2009 | CN100518747C Matrix metalloprotease inhibitor |
| 07/29/2009 | CN100518739C A retroviral immunotherapy |
| 07/29/2009 | CN100518735C Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/29/2009 | CN100518727C Preparaton method of anticancer medicine colchicin microsphere freeze dried agent |
| 07/28/2009 | US7566781 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide |
| 07/28/2009 | US7566770 Humanized collagen antibodies and related methods |
| 07/28/2009 | US7566766 Use of phage display libraries in a screening assay in order to determine the identity of peptides sequences which enhance the delivery of the bacteriophage through tissue, such as epithelial cells lining the lumen of gastrointestinal tract |
| 07/28/2009 | US7566764 Truncated BARD1 protein, and its diagnostic and therapeutic uses |
| 07/28/2009 | US7566734 Imidazolyl derivatives |
| 07/28/2009 | US7566721 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
| 07/28/2009 | US7566720 9-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one; glycogen synthase kinase 3 beta inhibitors; nerve growth factors; neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; tauopathies; stroke; vision defects;antidiabetic agent; anticarcinogenic |
| 07/28/2009 | US7566711 Dimethylcarbamic acid 4-(2-allyl,1-benzylcarbamoyl,8-(2,4-difluorobenzyl)-4,7-dioxo-octahydropyrazino(2,1-c)(1,2,4)triazin-6-yl)methylphen-4-yl ester; combinatorial libraries; anticarcinogenic agents; colorectal cancer; cell growth regulation; antiproliferiative/-apoptosis agents; Wnt transcription |
| 07/28/2009 | US7566706 Drug delivery methods of 17-ammonium hydroquinone ansamycin analogs with improved solubility and air stability; antiproliferative and anticarcinogenic agents |
| 07/28/2009 | US7566698 Extracted from plants such as Ningxia Lycium barbarum L. and/or Lycium chinense Mill; glucosyltransferases, cellulases; provitamin C with improved stability and bioavailability; ultraviolet damage protector; antiwrinkling; whitening |
| 07/28/2009 | US7566694 Anti-pathogen treatments |
| 07/28/2009 | US7566568 Method for generating highly active human dendritic cells from peripheral blood mononuclear cells |
| 07/28/2009 | US7566566 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
| 07/28/2009 | US7566559 Human cyclin-dependent kinase (hPNQALRE) |
| 07/28/2009 | US7566453 Methods for treating melanomas |
| 07/28/2009 | US7566449 Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins |
| 07/28/2009 | US7566444 Versatile hydrophilic dyes |
| 07/28/2009 | CA2505964C Pharmaceutical compositions and dosage forms of thalidomide |
| 07/28/2009 | CA2472008C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 07/28/2009 | CA2443012C Use of pyridoindolone derivatives for preparing medicines |
| 07/28/2009 | CA2399209C Process for preparation of indolopyrrolocarbazole derivative, intermediates in the preparation and process for preparation of the intermediates |
| 07/28/2009 | CA2255804C Antitumoral method by administration of partricin derivatives |
| 07/28/2009 | CA2178592C Long-acting injection suspensions and a process for their preparation |
| 07/23/2009 | WO2009092050A2 Pterin based therapies for inflammatory conditions |
| 07/23/2009 | WO2009091939A1 Imidazopyrazinol derivatives for the treatment of cancers |
| 07/23/2009 | WO2009091898A2 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| 07/23/2009 | WO2009091810A1 Methods for inhibiting angiogenesis using egfl8 antagonists |
| 07/23/2009 | WO2009091788A1 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 07/23/2009 | WO2009091594A1 Crystalline forms of lestaurtinib |
| 07/23/2009 | WO2009091476A1 Compositions and methods for treating cancers |
| 07/23/2009 | WO2009090961A1 Agent for prevention of alcoholic hepatopathy |
| 07/23/2009 | WO2009090933A1 Virus growing in hypoxic cell or virus vector expressing gene therein |
| 07/23/2009 | WO2009090903A1 Platinum complex compound and utilization of the same |
| 07/23/2009 | WO2009090661A1 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders |
| 07/23/2009 | WO2009090623A1 Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological applications thereof |
| 07/23/2009 | WO2009090277A1 Water-soluble ruthenium complexes comprising hydrosoluble phosphines and purine bases |
| 07/23/2009 | WO2009090039A1 Pyridazine fungicides |
| 07/23/2009 | WO2009090024A1 Solid forms of ortataxel |
| 07/23/2009 | WO2009090023A1 Crystalline form i of ortataxel |
| 07/23/2009 | WO2009089900A1 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives |
| 07/23/2009 | WO2009089858A1 COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART |
| 07/23/2009 | WO2009089851A1 Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments |
| 07/23/2009 | WO2009089810A1 Production and use of antitumoral cyclodepsipeptides |
| 07/23/2009 | WO2009073575A3 Methods for treating induced cellular proliferative disorders |
| 07/23/2009 | WO2009070331A3 Compounds and methods for the selective inhibition of abcb1, abcc1 and abcg2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors |
| 07/23/2009 | WO2009068906A3 Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| 07/23/2009 | WO2009067690A3 Methods for safe and effective treatment using oxazaphosphorine drugs |
| 07/23/2009 | WO2009066182A3 Method of treating cancer |
| 07/23/2009 | WO2009065028A3 Brca1-based breast or ovarian cancer prevention agents and methods of use |
| 07/23/2009 | WO2009063070A3 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 07/23/2009 | WO2009059309A3 Furin-cleavable peptide linkers for drug-ligand conjugates |
| 07/23/2009 | WO2009052379A3 Improved antitumoral treatments |
| 07/23/2009 | WO2009052081A4 Antibodies that bind il-4 and/or il-13 and their uses |
| 07/23/2009 | WO2009046845A3 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 07/23/2009 | WO2009045360A3 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| 07/23/2009 | WO2009043523A3 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 07/23/2009 | WO2009040084A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009040034A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009039973A3 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/23/2009 | WO2009038771A3 Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers |
| 07/23/2009 | WO2009033816A3 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 07/23/2009 | WO2009033773A3 Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
| 07/23/2009 | WO2009033761A3 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent |
| 07/23/2009 | WO2009013348A3 Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
| 07/23/2009 | WO2009002808A3 Quinazolinone compounds and methods of use thereof |
| 07/23/2009 | WO2008136774A8 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide |
| 07/23/2009 | WO2008136748A8 Tumour growth inhibitory compounds and methods of their use |
| 07/23/2009 | WO2008136736A8 Immunoregulatory structures from normally occurring proteins |
| 07/23/2009 | WO2008133684A8 Antibodies that bind both il-17a and il-17f and methods of using the same |
| 07/23/2009 | WO2008127193A8 Metalled sirnas for facilitated targeting of suboptimal mrna sequences |
| 07/23/2009 | WO2007094027A8 Methods for the diagnosis of proliferative and/or conformational diseases |
| 07/23/2009 | WO2007092939A8 Antigenic gm-csf peptides and antibodies to gm-csf |
| 07/23/2009 | WO2007090294A8 Anti-bfa4 monoclonal antibodies and for cancer diagnostics and treatment |
| 07/23/2009 | WO2007086093A8 Inhibitors of cell migration mediated by h-prune-gsk-3 complex and uses in antitumoral therapy |
| 07/23/2009 | US20090188000 Gene family (lbfl313) associated with pancreatic cancer |
| 07/23/2009 | US20090187007 Using estrogen receptor specific immunoglobulins to treat cell proliferative disorders of mammary glands |
| 07/23/2009 | US20090186951 Identification of novel pathways for drug development for lung disease |
| 07/23/2009 | US20090186950 13,13-Dimethyl-des-C,D Analogs of 1Alpha,25-Dihydroxy-19-Nor-Vitamin D3 Compounds and Topical Composition Dosage Forms and Methods of Treating Skin Conditions Thereof |
| 07/23/2009 | US20090186944 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
| 07/23/2009 | US20090186938 Antitumoral dihydropyran-2-one compounds |
| 07/23/2009 | US20090186930 Novel imidazole derivatives, preparation and user thereof as medicine |
| 07/23/2009 | US20090186929 Method and agent for inducing apoptosis/cell death in leukemia cells |
| 07/23/2009 | US20090186915 Compositions and methods for treatment of glioblastoma, gliosarcoma, NSCLC, and head and neck cancer |
| 07/23/2009 | US20090186913 Tetrahalogenated compounds useful as inhibitors of angiogenesis |
| 07/23/2009 | US20090186906 N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer |
| 07/23/2009 | US20090186905 Anaplastic lymphoma kinase modulators and methods of use |
| 07/23/2009 | US20090186897 Phthalazinone derivatives |
| 07/23/2009 | US20090186893 inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides |
| 07/23/2009 | US20090186892 Methods for treating lung cancers |
| 07/23/2009 | US20090186890 Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative |
| 07/23/2009 | US20090186888 Novel fused pyrrolocarbazoles |